42 results about "Gelsolin" patented technology

The invention relates to the use of gelsolin to treat inflammatory diseases (e.g., rheumatoid arthritis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of inflammatory diseases (e.g., rheumatoid arthritis).

Provided are methods of using gelsolin and active fragments thereof to neutralize, treat or prevent the pathogenic effects of lipopolysaccharide (LPS) endotoxins released from gram-negative bacteria, including massive activation of inflammatory response in a patient and the resulting lethal septic shock. The provided gelsolin binds LPS from various bacteria with high affinity, decreasing circulating LPS and neutralizes its deleterious biological effects. Consequently, the provided gelsolin replacement therapy offers a method for the prevention of LPS-induced mortality in the patient.

The invention relates to the use of gelsolin to treat neurologic diseases (e.g., multiple sclerosis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of neurologic diseases.

The invention relates to methods for determining the clinical outcome of a patient suffering ischemic stroke, for designing an individual therapy and for diagnosing a silent cerebrovascular disease comprising determining the levels of a marker selected from DPYSL2, gelsolin, CysA, or a combination thereof, the altered expression of which in relation to a reference value allows determining the clinical outcome of a patient suffering ischemic stroke, designing for designing an individual therapy or diagnosing a silent cerebrovascular disease. Furthermore, the invention relates to a kit comprising a reagent for detecting the level of a marker selected from DPYSL2, gelsolin, CysA, or a combination thereof and to the use of the said kit in the methods of the invention.

The invention relates to a method for determining the presence of renal damage in an individual and also to a method for detecting one or several proteins selected from the list comprising Reg3B, fetuin B, Ras-related GTP-binding protein A serine protease inhibitor A3L, subunit 1 of COP9, gamma subunit of ATP synthase, gelsolin, ribonuclease UK114, aminoacylase 1A, alpha-enolase, keratin 5, parvalbumin alpha, ribonuclease 4 or serine protease inhibitor A3K. The renal damage may be acute renal failure. Said renal pathologies may be caused by the administration of a nephrotoxic agent, wherein the nephrotoxic agent may be an aminoglycoside antibiotic such as gentamicin, or cisplatin. The invention also provides means to differentiate the renal damage or renal failure induced by gentamicin from that induced by cisplatin, through the biochemical analysis of the urinary level of Reg3B and/or gelsolin, or fragments thereof.

The invention relates to a method for expressing and purifying human cytoplasmic gelsolin (hcGSN). A recombinant expression vector pET-15b-hcGSN is constructed by designing a primer, IPTG inducible expression is used for obtaining N-end recombinant objective protein hcGSN with His labels, and recombinant protein hcGSN with high purity can be obtained through nickel ion affinity chromatography one-step purification. According to the method for expressing and purifying the hcGSN, cleavage sites of thrombin are further designed between the His labels and amino acid sequences of the hcGSN, and the His labels can be removed through the thrombin as needed. The method for producing and recombining the hcGSN is provided, massive soluble expression of the hcGSN in Escherichia coli is achieved, and the recombinant hcGSN with high purity can be efficiently, easily, conveniently and stably obtained through nickel ion affinity chromatography purification. The recombinant protein provides a material basis for related scientific researches and is possibly applied to prevention and treatment of diseases such as tumors and Alzheimer diseases in future.

The invention provides application of urine gelsolin (GSN) and polypeptide fragments of the urine gelsolin (GSN) in lung adenocarcinoma, and in particular relates to application of the urine gelsolin(GSN) and the polypeptide fragments of the urine gelsolin (GSN) in preparation of a preparation for detecting and auxiliary diagnosis of the lung adenocarcinoma. Researches confirm that compared witha normal control and a lung adenocarcinoma patient group, the urine gelsolin (GSN) is expressed in a low level in urine of a lung adenocarcinoma patient, and can be used for detection and auxiliary diagnosis of the lung adenocarcinoma. The advantages of non-invasive acquisition, large-scale repeated sampling, and convenient preservation of a urine specimen are played, and the urine specimen is used to detect the urine gelsolin (GSN) and the polypeptide fragments of the urine gelsolin (GSN).

The invention relates to application of miRNA in regulating and controlling expression levels of Gelsolin and application in antiplatelet treatment, and miRNA is miR-124. The invention further relatesto a method for screening reagents for regulating miRNA in blood platelet to screen potential antiplatelet treatment medicines. Screening tests show that ligustrazine, panax notoginseng saponins andaspirin can adjust the level of miR-124 in blood platelet cells, and thus functions are brought into play in antiplatelet treatment.

The invention belongs to the field of nanoparticle preparation in the biochemical technique, and particularly relates to a gelsolin inclusion and nano-crystallization method and a suspension. According to the implementation scheme, in parts by weight, under the normal temperature condition, gelsolin and hydroxypropyl-beta-cyclodextrin are added into a mortar in a proportion of 1:10, and a small amount of purified water is added for grinding for 4h; and then, a mixture of the gelsolin and hydroxypropyl-beta-cyclodextrin is filtered and freeze-dried to obtain a cyclodextrin/gelsolin inclusion complex. The inclusion complex is nano-crystallized to obtain the nanosuspension of a gelsolin-cyclodextrin inclusion complex. The method of the invention does not use an organic solvent or toxic cross-linking agent, has simple operation, a good inclusion effect and high repeatability, and is safe and reliable.

The present invention relates to a method for screening a risk group of a hematologic disease and a method for analyzing the prognosis of a hematologic disease based on the measurement of the level of gelsolin mRNA in buffy coat of peripheral blood or a bone marrow aspirate. The use of the present invention enables the screening of a risk group of a hematologic disease and the analysis of prognosis of a patient with a hematologic disease in an easy and accurate manner.

The invention relates to novel application of a gelsolin detection substance, in particular to application of the gelsolin detection substance in preparation of a reagent for uterine cancer disease risk assessment or prognosis effect assessment. The gelsolin detection substance is made into a detection reagent; the level of gelsolin in blood of a subject is detected, and then the level is compared with a preset value, so the risk of the subject suffering from the uterine cancer is obtained, or the prognosis effect of a patient suffering from the uterine cancer is evaluated; and experiments show that the gelsolin level in a specific range is closely related to the occurrence or poor prognosis of the uterine cancer.

The invention provides a cyclodextrin soluble gelsolin generation device and method and an atomization system. Airflow generated by an air compressor sequentially passes through a condenser and a second filter and enters an atomizer, and the atomizer atomizes cyclodextrin soluble gelsolin through compressed air. According to the invention, the function and effect of gelsolin are utilized, a cyclodextrin water-soluble gelsolin inclusion compound is prepared, the cyclodextrin water-soluble gelsolin inclusion compound is atomized and inhaled into a certain body cavity or a human body through an atomization device for generating clean compressed air, and the inclusion compound can release the gelsolin in the human body after entering the human body.

Provided are in vivo and in vitro methods for identifying or detecting a synapse which has been activated, or assessing the level of activation of a synapse, which method comprises: (i) determining the presence and\or amount, in a morphologically specialised postsynaptic site in the synapse (e.g. a dendritic spine), of a detectable cellular component associated with the activation (which is a ‘tag’ or ‘marker’ for the activation e.g. an actin-cytoskeleton interacting protein such as profilin II or gelsolin), and (ii) correlating the result of the determination with synaptic activation. Such assays can be useful in identifying processes involved in LTP, and also more generally in identifying modulators of synaptic activation or transmission, and hence cognitive function.

The present invention proposes secretory gelsolin (pGSN) as a plasma biomarker for evaluating distal metastasis of colorectal cancer. The present invention uses a special amino acid sequence of pGSN to fabricate a pGSN-specific polyclonal antibody. The present invention further uses the pGSN-specific polyclonal antibody to develop a high-specificity ELISA method and an assay kit thereof for evaluating distal metastasis of colorectal cancer.